- Home
- HEPS vs ESPR Comparison
HEPS vs ESPR Comparison
Compare HEPS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | ESPR |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.5M | 793.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HEPS | ESPR |
|---|---|---|
| Price | $2.62 | $3.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.07 | ★ $6.67 |
| AVG Volume (30 Days) | 350.8K | ★ 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.58 | $27.49 |
| Revenue Next Year | $32.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.69 |
| 52 Week High | $3.85 | $4.18 |
Technical Indicators
Market Signals| Indicator | HEPS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 55.09 |
| Support Level | $2.58 | $3.16 |
| Resistance Level | $2.93 | $3.63 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 20.70 | 86.46 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.